Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B

H. Masand, Vijay and A. Al-Hussain, Sami and M. Rathore, Mithilesh and D. Thakur, Sumer and Akasapu, Siddhartha and Samad, Abdul and A. Al-Mutairi, Aamal and E. A. Zaki, Magdi (2022) Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B. International Journal of Molecular Sciences, 23.

[img] Text (Research Article)
ijms-23-14527-v2.pdf - Published Version

Download (5MB)
Official URL:


Aurora kinase B (AKB) is a crucial signaling kinase with an important role in cell division. Therefore, inhibition of AKB is an attractive approach to the treatment of cancer. In the present work, extensive quantitative structure–activity relationships (QSAR) analysis has been performed using a set of 561 structurally diverse aurora kinase B inhibitors. The Organization for Economic Cooperation and Development (OECD) guidelines were used to develop a QSAR model that has high statistical performance (R2tr = 0.815, Q2LMO = 0.808, R2ex = 0.814, CCCex = 0.899). The seven-variable-based newly developed QSAR model has an excellent balance of external predictive ability (Predictive QSAR) and mechanistic interpretation (Mechanistic QSAR). The QSAR analysis successfully identifies not only the visible pharmacophoric features but also the hidden features. The analysis indicates that the lipophilic and polar groups—especially the H-bond capable groups—must be present at a specific distance from each other. Moreover, the ring nitrogen and ring carbon atoms play important roles in determining the inhibitory activity for AKB. The analysis effectively captures reported as well as unreported pharmacophoric features. The results of the present analysis are also supported by the reported crystal structures of inhibitors bound to AKB.

Item Type: Article
Uncontrolled Keywords: aurora kinase B; QSAR; pharmacophore modeling
Subjects: Q Science > QD Chemistry
R Medicine > RS Pharmacy and materia medica
Depositing User: ePrints deposit
Date Deposited: 11 Sep 2023 13:03
Last Modified: 11 Sep 2023 13:03

Actions (login required)

View Item View Item